<?xml version='1.0' encoding='utf-8'?>
<document id="29145924"><sentence text="Pharmacokinetic interaction between bedaquiline and clofazimine in patients with drug-resistant tuberculosis."><entity charOffset="36-47" id="DDI-PubMed.29145924.s1.e0" text="bedaquiline" /><entity charOffset="52-63" id="DDI-PubMed.29145924.s1.e1" text="clofazimine" /><pair ddi="false" e1="DDI-PubMed.29145924.s1.e0" e2="DDI-PubMed.29145924.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29145924.s1.e0" e2="DDI-PubMed.29145924.s1.e1" /></sentence><sentence text="Bedaquiline (BDQ) and clofazimine (CFZ) are both recommended for treating drug-resistant tuberculosis (DR-TB)"><entity charOffset="0-11" id="DDI-PubMed.29145924.s2.e0" text="Bedaquiline" /><entity charOffset="13-16" id="DDI-PubMed.29145924.s2.e1" text="BDQ" /><entity charOffset="22-33" id="DDI-PubMed.29145924.s2.e2" text="clofazimine" /><entity charOffset="35-38" id="DDI-PubMed.29145924.s2.e3" text="CFZ" /><pair ddi="false" e1="DDI-PubMed.29145924.s2.e0" e2="DDI-PubMed.29145924.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29145924.s2.e0" e2="DDI-PubMed.29145924.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29145924.s2.e0" e2="DDI-PubMed.29145924.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29145924.s2.e0" e2="DDI-PubMed.29145924.s2.e3" /><pair ddi="false" e1="DDI-PubMed.29145924.s2.e1" e2="DDI-PubMed.29145924.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29145924.s2.e1" e2="DDI-PubMed.29145924.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29145924.s2.e1" e2="DDI-PubMed.29145924.s2.e3" /><pair ddi="false" e1="DDI-PubMed.29145924.s2.e2" e2="DDI-PubMed.29145924.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29145924.s2.e2" e2="DDI-PubMed.29145924.s2.e3" /></sentence><sentence text=" As CFZ is an inhibitor of the cytochrome P450 isoenzyme 3A4 (CYP3A4) in vitro, and BDQ a substrate of CYP3A4, there is a potential for pharmacokinetic (PK) drug-drug interaction that may result in increased BDQ exposure when co-administered with CFZ, which could increase the toxicity of BDQ"><entity charOffset="84-86" id="DDI-PubMed.29145924.s3.e0" text="BDQ" /><entity charOffset="208-210" id="DDI-PubMed.29145924.s3.e1" text="BDQ" /><entity charOffset="289-291" id="DDI-PubMed.29145924.s3.e2" text="BDQ" /><entity charOffset="4-6" id="DDI-PubMed.29145924.s3.e3" text="CFZ" /><entity charOffset="247-249" id="DDI-PubMed.29145924.s3.e4" text="CFZ" /><pair ddi="false" e1="DDI-PubMed.29145924.s3.e3" e2="DDI-PubMed.29145924.s3.e3" /><pair ddi="false" e1="DDI-PubMed.29145924.s3.e3" e2="DDI-PubMed.29145924.s3.e0" /><pair ddi="false" e1="DDI-PubMed.29145924.s3.e3" e2="DDI-PubMed.29145924.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29145924.s3.e3" e2="DDI-PubMed.29145924.s3.e4" /><pair ddi="false" e1="DDI-PubMed.29145924.s3.e3" e2="DDI-PubMed.29145924.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29145924.s3.e0" e2="DDI-PubMed.29145924.s3.e0" /><pair ddi="false" e1="DDI-PubMed.29145924.s3.e0" e2="DDI-PubMed.29145924.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29145924.s3.e0" e2="DDI-PubMed.29145924.s3.e4" /><pair ddi="false" e1="DDI-PubMed.29145924.s3.e0" e2="DDI-PubMed.29145924.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29145924.s3.e1" e2="DDI-PubMed.29145924.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29145924.s3.e1" e2="DDI-PubMed.29145924.s3.e4" /><pair ddi="false" e1="DDI-PubMed.29145924.s3.e1" e2="DDI-PubMed.29145924.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29145924.s3.e4" e2="DDI-PubMed.29145924.s3.e4" /><pair ddi="false" e1="DDI-PubMed.29145924.s3.e4" e2="DDI-PubMed.29145924.s3.e2" /></sentence><sentence text="" /><sentence text="We assessed the effect of co-administered CFZ on BDQ bioavailability, or on clearance of BDQ and its N-monodesmethyl metabolite (M2), in patients with DR-TB using a population PK model developed from data of patients with DR-TB"><entity charOffset="101-116" id="DDI-PubMed.29145924.s5.e0" text="N-monodesmethyl" /><entity charOffset="49-63" id="DDI-PubMed.29145924.s5.e1" text="BDQ" /><entity charOffset="89-103" id="DDI-PubMed.29145924.s5.e2" text="BDQ" /><entity charOffset="42-56" id="DDI-PubMed.29145924.s5.e3" text="CFZ" /><pair ddi="false" e1="DDI-PubMed.29145924.s5.e3" e2="DDI-PubMed.29145924.s5.e3" /><pair ddi="false" e1="DDI-PubMed.29145924.s5.e3" e2="DDI-PubMed.29145924.s5.e1" /><pair ddi="false" e1="DDI-PubMed.29145924.s5.e3" e2="DDI-PubMed.29145924.s5.e2" /><pair ddi="false" e1="DDI-PubMed.29145924.s5.e3" e2="DDI-PubMed.29145924.s5.e0" /><pair ddi="false" e1="DDI-PubMed.29145924.s5.e1" e2="DDI-PubMed.29145924.s5.e1" /><pair ddi="false" e1="DDI-PubMed.29145924.s5.e1" e2="DDI-PubMed.29145924.s5.e2" /><pair ddi="false" e1="DDI-PubMed.29145924.s5.e1" e2="DDI-PubMed.29145924.s5.e0" /><pair ddi="false" e1="DDI-PubMed.29145924.s5.e2" e2="DDI-PubMed.29145924.s5.e2" /><pair ddi="false" e1="DDI-PubMed.29145924.s5.e2" e2="DDI-PubMed.29145924.s5.e0" /></sentence><sentence text=" This was a secondary analysis of a study designed to explore drug-drug interactions between BDQ and antiretrovirals"><entity charOffset="93-95" id="DDI-PubMed.29145924.s6.e0" text="BDQ" /></sentence><sentence text="" /><sentence text="Of 46 participants, 30 were on concomitant CFZ when intensive PK sampling of BDQ was done"><entity charOffset="77-79" id="DDI-PubMed.29145924.s8.e0" text="BDQ" /><entity charOffset="43-45" id="DDI-PubMed.29145924.s8.e1" text="CFZ" /><pair ddi="false" e1="DDI-PubMed.29145924.s8.e1" e2="DDI-PubMed.29145924.s8.e1" /><pair ddi="false" e1="DDI-PubMed.29145924.s8.e1" e2="DDI-PubMed.29145924.s8.e0" /></sentence><sentence text=" CFZ did not have a statistically significant effect on BDQ bioavailability (-9"><entity charOffset="56-58" id="DDI-PubMed.29145924.s9.e0" text="BDQ" /><entity charOffset="1-3" id="DDI-PubMed.29145924.s9.e1" text="CFZ" /><pair ddi="false" e1="DDI-PubMed.29145924.s9.e1" e2="DDI-PubMed.29145924.s9.e1" /><pair ddi="false" e1="DDI-PubMed.29145924.s9.e1" e2="DDI-PubMed.29145924.s9.e0" /></sentence><sentence text="1%, 90%CI -22" /><sentence text="8 to +7" /><sentence text="1; P = 0" /><sentence text="19) or on BDQ and M2 clearance (+12"><entity charOffset="10-12" id="DDI-PubMed.29145924.s13.e0" text="BDQ" /></sentence><sentence text="2%, 90%CI -13" /><sentence text="7 to +38; P = 0" /><sentence text="32)" /><sentence text="" /><sentence text="We did not find a statistically significant PK drug-drug interaction between BDQ and CFZ, but cannot exclude a potentially clinically relevant interaction due to the wide confidence intervals of the estimated interaction effects"><entity charOffset="77-79" id="DDI-PubMed.29145924.s18.e0" text="BDQ" /><entity charOffset="85-87" id="DDI-PubMed.29145924.s18.e1" text="CFZ" /><pair ddi="false" e1="DDI-PubMed.29145924.s18.e0" e2="DDI-PubMed.29145924.s18.e0" /><pair ddi="false" e1="DDI-PubMed.29145924.s18.e0" e2="DDI-PubMed.29145924.s18.e1" /></sentence><sentence text="" /></document>